Skip to main content

Table 3 Clinical outcomes at one year in patients undergoing PCI [n(%)]

From: Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

Variables Fondaparinux (n = 422) Enoxaparin (n = 453) P
MACCEa 46 (10.9) 57 (12.6) 0.433
Death or MI 18 (4.3) 24 (5.3) 0.475
Death 2 (0.5) 7 (1.5) 0.116
MI 16 (3.8) 17 (3.8) 0.976
TVR 23 (5.5) 28 (6.2) 0.645
Stroke 7 (1.7) 9 (2.0) 0.717
30 day    
 Major bleeding 1 (0.23) 4 (0.88) 0.429
 All bleedingb 4 (0.95) 13 (2.9) 0.040
1 year    
 Major bleeding 1 (0.23) 5 (1.1) 0.253
 All bleedingb 10 (2.4) 25 (5.5) 0.018
  1. MI Myocardial infarction, TVR Target vessel revascularization. aMACCE: including death from cardiovascular causes, non-fatal myocardial infarction and target vessel revascularization. bAll bleeding was defined using the TIMI definition. P < 0.05 was considered to indicate statistical significance